TNX-103 clinical trials

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

This study looks at a new drug, TNX-103, for people in the UK with high blood pressure in the lungs combined with a type of heart failure (PH-HFpEF). It aims to see if the drug helps them walk further, compared to a dummy pill.